Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 Shares

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the transaction, the chief executive officer now directly owns 195,307 shares in the company, valued at $8,708,739.13. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Dominick Colangelo also recently made the following trade(s):

• On Wednesday, March 13th, Dominick Colangelo sold 17,500 shares of Vericel stock. The stock was sold at an average price of $44.67, for a total value of $781,725.00.

Vericel Stock Down 0.3 %

VCEL stock traded down $0.12 during trading on Friday, reaching $43.74. The company’s stock had a trading volume of 521,989 shares, compared to its average volume of 554,959. The company has a market capitalization of $2.12 billion, a P/E ratio of -480.33 and a beta of 1.71. The company’s fifty day moving average is $47.64 and its 200-day moving average is $40.30. Vericel Co. has a 1 year low of $29.24 and a 1 year high of $53.05.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.08. The firm had revenue of $65.00 million during the quarter, compared to analyst estimates of $64.28 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The business’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.12 earnings per share. Analysts anticipate that Vericel Co. will post 0.09 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. MCF Advisors LLC lifted its holdings in shares of Vericel by 86.1% in the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 223 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Vericel in the 4th quarter valued at about $33,000. Tower Research Capital LLC TRC lifted its holdings in shares of Vericel by 174.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,668 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,060 shares during the last quarter. GAMMA Investing LLC bought a new position in shares of Vericel in the 4th quarter valued at about $65,000. Finally, Shell Asset Management Co. bought a new position in shares of Vericel in the 4th quarter valued at about $74,000.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. HC Wainwright raised their target price on Vericel from $46.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Truist Financial reiterated a “buy” rating and issued a $54.00 price target on shares of Vericel in a research note on Tuesday, March 26th. Finally, TheStreet upgraded Vericel from a “d+” rating to a “c-” rating in a research note on Monday, January 29th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.40.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.